Fig 1: TrkB/Akt/Fyn signaling is required for the phosphorylation of NMDA receptors in vitro.a–e After normal or transfected HT22 cells were pretreated with brain-derived neurotrophic factor (BDNF) and Mn, the levels of phospho-Akt and phospho-Fyn, and Akt and Fyn expression were evaluated by western blotting. f–j After normal or transfected HT22 cells were pretreated with BDNF and Mn, the levels of phospho-GluN2B and phospho-GluN2A, and the expression of GluN2B and GluN2A were evaluated by western blotting. n = 4. β-actin was used as a loading control. **P < 0.01, and *P < 0.05 compared to their control counterparts; ##P < 0.01 compared to their Mn-treated cells; ΔΔP < 0.01, and ΔP < 0.05 for comparison between their BDNF-pretreated and Mn-treated cells.
Fig 2: Brain-derived neurotrophic factor (BDNF) interfered with the interaction of α-Syn and TrkB.a, b After pretreatment with BDNF and Mn in HT22 cells, representative images of PLA show the interaction between α-Syn and TrkB (red spots), and the nucleus was stained in blue (DAPI). Scale bars = 50 μm. c, d The immunoprecipitation analysis of α-Syn and TrkB is shown. e–g After treating the mice with Mn, the levels of BDNF and TrkB were evaluated by western blotting. n = 6. h–j For HT22 cells transfected with the LV-α-Syn shRNA, the levels of BDNF and TrkB were evaluated by western blotting after Mn treatment. k–m After pretreatment with BDNF and Mn in HT22 cells, the levels of TrkB and α-Syn expression were evaluated by western blotting. n = 4. **P < 0.01, and *P < 0.05 compared to their control counterparts; ##P < 0.01, and #P < 0.05 for comparison between the Mn treatment group.
Supplier Page from Abcam for Human BDNF peptide